局部晚期鼻咽癌诱导化疗后调强放疗靶区减量的长期结果:一项前瞻性、多中心、随机试验
该前瞻性随机试验在6家中国医院纳入212例III-IVB期鼻咽癌患者,随机分为诱导化疗前靶区组(pre-IC组)和诱导化疗后靶区组(post-IC组),均接受2周期诱导化疗+同步放化疗及根治性调强放疗。中位随访98.4个月,post-IC组在局部区域复发风险方面不劣于pre-IC组,且口干燥症和听力损伤发生率更低,生活质量在认知功能及口干、唾液粘稠、不适感等症状方面显著改善。
要点
- 局部晚期鼻咽癌诱导化疗后缩小调强放疗靶区,局部区域复发风险不劣于诱导化疗前靶区。
- post-IC组口干燥症和听力损伤发生率显著低于pre-IC组,无4级晚期毒性。
- post-IC组认知功能及口干、唾液粘稠、不适感等症状生活质量显著改善。
核心结论
- 长期随访证实,局部晚期鼻咽癌诱导化疗后缩小调强放疗靶区在局部区域复发风险方面不劣于诱导化疗前靶区,并可能改善生活质量、减轻晚期毒性。
研究设计与样本
- 前瞻性、多中心、随机临床试验,在6家中国医院纳入212例III-IVB期鼻咽癌患者,随机分配至pre-IC组或post-IC组。
- eligible患者接受2周期诱导化疗+同步放化疗,所有患者接受根治性调强放疗。
- pre-IC组和post-IC组分别根据诱导化疗前和诱导化疗后肿瘤范围勾画鼻咽大体肿瘤体积。
主要发现
- 中位随访98.4个月,pre-IC组97例中32例(32.9%)、post-IC组115例中33例(28.7%)出现治疗失败或死亡。
- pre-IC组和post-IC组的5年总生存率分别为78.2%和83.3%,无进展生存率分别为72.0%和78.1%,局部区域无复发生存率分别为90.2%和93.5%,无远处转移生存率分别为78.1%和82.1%。
- 无患者发生4级晚期毒性;晚期放射性毒性主要表现为1-2级皮下纤维化、听力下降、耳鸣和口干燥症,3级晚期毒性包括口干燥症和听力下降。
- pre-IC组口干燥症和听力损伤发生率显著高于post-IC组。
- 与pre-IC组相比,post-IC组认知功能(P=0.045)及口干(P=0.004)、唾液粘稠(P=0.047)、不适感(P=0.041)等症状显著改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The objective of this study was to estimate the long-term survival, late toxicity profile, and quality of life of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) treated with combined induction chemotherapy (IC) and concurrent chemoradiotherapy from a clinical trial focused on reducing the target volume of intensity modulated radiation therapy (IMRT). METHODS AND MATERIALS: This prospective, randomized clinical trial was conducted across 6 Chinese hospitals and included 212 patients with stage III-IVB NPC who were randomly allocated to a pre-IC or post-IC group. Eligible patients were treated with 2 cycles of IC + CCRT. All patients underwent radical IMRT. Gross tumor volumes of the nasopharynx were delineated according to pre-IC and post-IC tumor extent in the pre-IC and post-IC groups, respectively. RESULTS: After a median follow-up of 98.4 months, 32 of 97 (32.9%) and 33 of 115 (28.7%) patients experienced treatment failure or died in the pre-IC and post-IC groups, respectively. None of the patients developed grade 4 late toxicity. Late radiation-induced toxicity predominantly manifested as grade 1 to 2 subcutaneous fibrosis, hearing loss, tinnitus, and xerostomia, whereas grade 3 late toxicity included xerostomia and hearing loss. The 5-year estimated overall, progression-free, locoregional recurrence-free, and distant metastasis-free survival rates in the pre-IC and post-IC groups were 78.2% versus 83.3%, 72.0% versus 78.1%, 90.2% versus 93.5%, and 78.1% versus 82.1%, respectively. The pre-IC group had a significantly higher incidence of xerostomia and hearing damage than the post-IC group. In terms of quality of life, compared with the pre-IC group, the post-IC group showed significant improvement in cognitive function (P = .045) and symptoms including dry mouth (P = .004), sticky saliva (P = .047), and feeling ill (P = .041). CONCLUSIONS: After long-term follow-up, we confirmed that reducing the target volumes of IMRT after IC in locoregionally advanced NPC showed no inferiority in terms of the risk of locoregional relapse and potentially improved quality of life and alleviated late toxicity.
引用
- Xiang L, Rong JF, Xin-Chen, et al. Reducing Target Volumes of Intensity Modulated Radiation Therapy After Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 37356553. doi:10.1016/j.ijrobp.2023.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。